Chemotherapy - Dacarbazine
Brand Names: DTIC-Dome, DTIC, DIC, Imidazole Carboxamide
Dacarbazine is a chemotherapy drug that is administered for the treatment of melanomas, neuroblastoma, and lymphomas. It functions as an alkylating chemotherapy agent, meaning it interferes with DNA reproduction in fast growing cells, thus preventing cell duplication and growth.
This drug is used primarily in the treatment of Hodgkin’s Disease. It is commonly used in conjunction with other chemotherapy drugs in the ABVD treatment regimen (adriamycin, bleomycin, oncovin, dacarbazine).
Drug Administration
Dacarbazine is given intravenously. The injection site should be monitored, as the drug is a known irritant. If any signs of inflammation are observed, a doctor should be alerted immediately.
Side Effects
Common side effects include peripheral neuropathy (numbness or tingling in the hands or feet), flu symptoms, and photosensitivity (sensitivity to light).
There is a small chance of developing leukemia as a secondary cancer, so the doctor should monitor patients after treatment stops.
For more information on Hodgkin's Lymphoma, please see the following pages:
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
